Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

749
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
749
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

516
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
516

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Performing multiple biomarker tests delays initiation of amyloid-targeting treatments.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Features predicting data exclusion in imaging studies of Alzheimer's disease.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Illuminating proinflammatory myeloid cells with PET tracers targeting GPR84.

Proceedings of the National Academy of Sciences of the United States of America·2026
Same author

Invited commentary on: "Employment disruption and missed workdays after neoadjuvant therapy receipt for high-risk gastrointestinal cancer".

Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract·2026
Same author

Usage and positivity rates of Alzheimer's disease biomarkers in a memory clinic.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Factors influencing accelerated progression in behavioral variant frontotemporal dementia.

Journal of neurology·2026
Same journal

Evidence for progressive neurodegeneration in iatrogenic cerebral amyloid angiopathy.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Human brain connectome profiles mediate the relationship between pathology burden and clinical phenotypes in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Kat5 cKO mouse replicates biological domain signatures associated with Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Evaluation of CSF and plasma tau species as fluid surrogate candidates for tau PET in prodromal to moderate Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Associations of self-reported obstructive sleep apnea with cognition and dementia risk in cognitively unimpaired middle-aged adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Inflammation profiles in Alzheimer's disease relate to cognition and neurodegeneration.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
查看所有相关文章

相关实验视频

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

生物标志物 生物标志物

Kavon J Sharifi1, Jessica Hu2, Hope Shimony1

  • 1Washington University School of Medicine, St. Louis, MO, USA.

Alzheimer's & dementia : the journal of the Alzheimer's Association
|December 24, 2025
PubMed
概括
此摘要是机器生成的。

一个便携式的低场核磁共振 (MRI) 显示出对接受莱卡尼马布治疗的阿尔茨海默病患者的监测有希望,准确检测ARIA-E (胀),但不能检测ARIA-H (微出血). 这可以改善患者和医疗机构获得必要的MRI扫描的机会.

更多相关视频

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

相关实验视频

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

702

科学领域:

  • 神经学 神经学
  • 医疗成像医学成像
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 莱卡内马布是FDA批准的阿尔茨海默病 (AD) 免疫疗法,需要定期对粉样蛋白相关成像异常 (ARIA) 的MRI监测.
  • ARIA可以表现为脑 (ARIA-E) 或微出血 (ARIA-H),需要及时检测.
  • 目前的MRI要求给患者,护理人员和医疗机构带来了重大后勤和可访问性挑战,可能会限制治疗机会.

研究的目的:

  • 为了评估超低场的可行性,便携式MRI系统用于基线和接受lecanemab治疗的患者的安全监测.
  • 为了比较便携式低场MRI与标准临床MRI的诊断性能,用于检测阿尔茨海默病患者的ARIA.

主要方法:

  • 纳入了31名接受或已停止使用lecanemab治疗的AD患者.
  • 参与者在临床MRI后一周内使用0.064T高精度Swoop®便携式MR成像系统进行了MRI扫描.
  • 追溯数据分析包括患者年龄,ARIA病史,以及低场和临床MRI扫描的读数.

主要成果:

  • 低场MRI系统在检测轻度和中度ARIA-E时实现了100%的灵敏度.
  • 该系统对ARIA-H (微出血) 不敏感.
  • 在临床MRI上检测到的偶发性体内血瘤在低场MRI上也可识别.

结论:

  • 超低电场,便携式MRI显示高灵敏度检测ARIA-E,一个关键的副作用的lecanemab.
  • 这项技术可以作为标准1.5/3T临床MRI扫描的适当替代品,可能减轻患者和医疗保健系统的负担.
  • 需要进一步验证,以确认其在莱卡尼马布治疗阿尔茨海默病患者的常规监测中的作用,特别是ARIA-H检测.